Literature DB >> 28154176

A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.

Guowei Yin1, Samantha Kistler1,2, Samuel D George3,4, Nora Kuhlmann5, Leslie Garvey6, Minh Huynh1,3,4, Rachel K Bagni6, Michael Lammers5, Channing J Der3,4, Sharon L Campbell7,3,4.   

Abstract

The KRAS GTPase plays a critical role in the control of cellular growth. The activity of KRAS is regulated by guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs), and also post-translational modification. Lysine 104 in KRAS can be modified by ubiquitylation and acetylation, but the role of this residue in intrinsic KRAS function has not been well characterized. We find that lysine 104 is important for GEF recognition, because mutations at this position impaired GEF-mediated nucleotide exchange. Because the KRAS K104Q mutant has recently been employed as an acetylation mimetic, we conducted a series of studies to evaluate its in vitro and cell-based properties. Herein, we found that KRAS K104Q exhibited defects in both GEF-mediated exchange and GAP-mediated GTP hydrolysis, consistent with NMR-detected structural perturbations in localized regions of KRAS important for recognition of these regulatory proteins. Despite the partial defect in both GEF and GAP regulation, KRAS K104Q did not alter steady-state GTP-bound levels or the ability of the oncogenic KRAS G12V mutant to cause morphologic transformation of NIH 3T3 mouse fibroblasts and of WT KRAS to rescue the growth defect of mouse embryonic fibroblasts deficient in all Ras genes. We conclude that the KRAS K104Q mutant retains both WT and mutant KRAS function, probably due to offsetting defects in recognition of factors that up-regulate (GEF) and down-regulate (GAP) RAS activity.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  GTPase-activating protein (GAP); Ras protein; guanine nucleotide exchange factor (GEF); nuclear magnetic resonance (NMR); post-translational modification; protein acetylation; signaling; tumorigenesis

Mesh:

Substances:

Year:  2017        PMID: 28154176      PMCID: PMC5377764          DOI: 10.1074/jbc.M116.762435

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS.

Authors:  S Mariana Margarit; Holger Sondermann; Brian E Hall; Bhushan Nagar; Andre Hoelz; Michelle Pirruccello; Dafna Bar-Sagi; John Kuriyan
Journal:  Cell       Date:  2003-03-07       Impact factor: 41.582

2.  A possible overestimation of the effect of acetylation on lysine residues in KQ mutant analysis.

Authors:  Hirofumi Fujimoto; Mariko Higuchi; Manabu Koike; Hirotaka Ode; Miroslav Pinak; Juraj Kotulic Bunta; Toshiyuki Nemoto; Takashi Sakudoh; Naoko Honda; Hideaki Maekawa; Kimiaki Saito; Kozo Tsuchida
Journal:  J Comput Chem       Date:  2011-11-10       Impact factor: 3.376

3.  Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism.

Authors:  John M Lambert; Que T Lambert; Gary W Reuther; Angeliki Malliri; David P Siderovski; John Sondek; John G Collard; Channing J Der
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

4.  Real-time in vitro measurement of intrinsic and Ras GAP-mediated GTP hydrolysis.

Authors:  Adam Shutes; Channing J Der
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

5.  Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination.

Authors:  Rachael Baker; Emily M Wilkerson; Kazutaka Sumita; Daniel G Isom; Atsuo T Sasaki; Henrik G Dohlman; Sharon L Campbell
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

Review 6.  Interactions between Ras proteins and their effectors.

Authors:  F McCormick; A Wittinghofer
Journal:  Curr Opin Biotechnol       Date:  1996-08       Impact factor: 9.740

Review 7.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

8.  A novel analytical method for in vivo phosphate tracking.

Authors:  Hong Gu; Sylvie Lalonde; Sakiko Okumoto; Loren L Looger; Anne Marie Scharff-Poulsen; Arthur R Grossman; Jens Kossmann; Iver Jakobsen; Wolf B Frommer
Journal:  FEBS Lett       Date:  2006-10-02       Impact factor: 4.124

Review 9.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Authors:  Dominico Vigil; Jacqueline Cherfils; Kent L Rossman; Channing J Der
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

Review 10.  Structures of Ras superfamily effector complexes: What have we learnt in two decades?

Authors:  Helen R Mott; Darerca Owen
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-04-01       Impact factor: 8.250

View more
  17 in total

Review 1.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 2.  Oncogenic Ras Isoforms Signaling Specificity at the Membrane.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Cancer Res       Date:  2017-12-22       Impact factor: 12.701

Review 3.  Regulation of large and small G proteins by ubiquitination.

Authors:  Henrik G Dohlman; Sharon L Campbell
Journal:  J Biol Chem       Date:  2019-10-23       Impact factor: 5.157

4.  K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function.

Authors:  Shufen Cao; Stacey Chung; SoonJeung Kim; Zhenlu Li; Danny Manor; Matthias Buck
Journal:  J Biol Chem       Date:  2019-02-21       Impact factor: 5.157

5.  Tissue-Specific Oncogenic Activity of KRASA146T.

Authors:  Asim K Bera; Jia Lu; Emily J Poulin; Yi-Jang Lin; Samantha Dale Strasser; Joao A Paulo; Tannie Q Huang; Carolina Morales; Wei Yan; Joshua Cook; Jonathan A Nowak; Douglas K Brubaker; Brian A Joughin; Christian W Johnson; Rebecca A DeStefanis; Phaedra C Ghazi; Sudershan Gondi; Thomas E Wales; Roxana E Iacob; Lana Bogdanova; Jessica J Gierut; Yina Li; John R Engen; Pedro A Perez-Mancera; Benjamin S Braun; Steven P Gygi; Douglas A Lauffenburger; Kenneth D Westover; Kevin M Haigis
Journal:  Cancer Discov       Date:  2019-04-05       Impact factor: 39.397

6.  Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects.

Authors:  Amy P Hsu; Agnes Donkó; Megan E Arrington; Muthulekha Swamydas; Danielle Fink; Arundhoti Das; Omar Escobedo; Vincent Bonagura; Paul Szabolcs; Harry N Steinberg; Jenna Bergerson; Amanda Skoskiewicz; Melanie Makhija; Joie Davis; Ladan Foruraghi; Cindy Palmer; Ramsay L Fuleihan; Joseph A Church; Avinash Bhandoola; Michail S Lionakis; Sharon Campbell; Thomas L Leto; Douglas B Kuhns; Steven M Holland
Journal:  Blood       Date:  2019-02-05       Impact factor: 22.113

7.  Thermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability.

Authors:  Kari Kopra; Salla Valtonen; Randa Mahran; Jonas N Kapp; Nazia Hassan; William Gillette; Bryce Dennis; Lianbo Li; Kenneth D Westover; Andreas Plückthun; Harri Härmä
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

Review 8.  Therapeutic targeting of RAS: New hope for drugging the "undruggable".

Authors:  Imran Khan; J Matthew Rhett; John P O'Bryan
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2019-10-31       Impact factor: 4.739

Review 9.  Post-translational modification of RAS proteins.

Authors:  Sharon L Campbell; Mark R Philips
Journal:  Curr Opin Struct Biol       Date:  2021-08-06       Impact factor: 6.809

10.  Monoubiquitination of KRAS at Lysine104 and Lysine147 Modulates Its Dynamics and Interaction with Partner Proteins.

Authors:  Vinay V Nair; Guowei Yin; Jerry Zhang; John F Hancock; Sharon L Campbell; Alemayehu A Gorfe
Journal:  J Phys Chem B       Date:  2021-04-30       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.